You are here

  • Home
  • Archive
  • Volume 33, Issue Suppl 3
  • #267 Quality-adjusted time without symptoms of disease or toxicity in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel versus carboplatin-paclitaxel in the ENGOT-EN6/GOG-3031/RUBY trial

Article Text

Article menu

Download PDFPDF

Oral Sessions
03. Endometrial cancer
#267 Quality-adjusted time without symptoms of disease or toxicity in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel versus carboplatin-paclitaxel in the ENGOT-EN6/GOG-3031/RUBY trial
Free
  1. Dana Chase1,
  2. Line Bjørge2,
  3. Robert L Coleman3,
  4. Oleksandr Zub4,
  5. Eirwen Miller5,
  6. Roberto Angioli6,
  7. Cara Mathews7,
  8. Lars C Hanker8,
  9. Michael G Teneriello3,
  10. Anna Reyners9,
  11. Matthew Powell10,
  12. Lucy Gilbert11,
  13. Noelle Cloven12,
  14. Sarah Gill13,
  15. Bradley J Monk14,
  16. Bhavana Pothuri15,
  17. Jamie Garside16,
  18. Odette Allonby17,
  19. Carolyn Mccourt10 and
  20. Mansoor Raza Mirza18
  1. 1University of California, Los Angeles (UCLA), Los Angeles, USA
  2. 2Haukeland University Hospital and University of Bergen, Bergen, Norway
  3. 3US Oncology Research, The Woodlands, USA
  4. 4Chernihiv Medical Center of Modern Oncology, Chernihiv, Ukraine
  5. 5Allegheny Health Network, Pittsburgh, USA
  6. 6Università di Roma – Campus Bio-Medico, Rome, Italy
  7. 7Women and Infants Hospital, Legoretta Cancer Center, Alpert Medical School of Brown University, Providence, USA
  8. 8AGO Study Group – University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany
  9. 9University Medical Center Groningen, University of Groningen, Groingen, The Netherlands
  10. 10Washington University St Louis, St Louis, USA
  11. 11McGill University Health Centre, Montreal, Canada
  12. 12Texas Oncology, Fort Worth, USA
  13. 13Lewis Cancer and Research Pavilion, Savannah, USA
  14. 14Honor Health Research Institiute, University of Arizona College of Medicine and Creighton University School of Medicine, Phoenix, USA
  15. 15Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, USA
  16. 16GSK, London, UK
  17. 17GSK, Mississauga, Canada
  18. 18Rigshospitalet, Copenhagen University Hospital and Nordic Society of Gynaecologic Oncology-Clinical Trial Unit, Copenhagen, Denmark

Abstract

Introduction/Background In the Phase III randomised, double-blind, multicentre RUBY study (NCT03981796), dostarlimab plus carboplatin-paclitaxel (dostarlimab+CP) resulted in significant improvement in progression-free survival versus CP alone in patients with primary advanced or recurrent endometrial cancer (AR EC). This post-hoc survival analysis explored quality-adjusted time without symptoms of disease or toxicity (Q-TWiST) in RUBY part 1.

Methodology Patients (N=494) were randomised 1:1 to receive dostarlimab+CP or placebo + CP every 3 weeks (Q3W) ≥6 cycles, then dostarlimab or placebo Q6W ≤3 years. Q-TWiST was calculated based on the safety population (patients receiving any amount of study drug; N=486) as the sum product of mean survival time (months; restricted to study follow-up time) in three mutually exclusive states and each state’s corresponding quality of life (EQ-5D-5L). States were time without symptoms of progression or toxicity (TWiST), toxicity (time from randomisation to progression during which patients experienced Grade ≥3 adverse events), and relapse (time from progression to any-cause death).

Results Overall, median follow-up duration was 20.5 months. For mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) patients, restricted mean Q-TWiST was significantly (P<0.001*) longer in the dostarlimab+CP versus CP group (difference: 5.4 months; actual restricted mean: 22.7 versus 17.2 months, respectively). Q-TWiST was also significantly (P<0.001*) longer in the dostarlimab+CP versus CP group for MMR-proficient/microsatellite-stable (MMRp/MSS) patients (difference: 2.6 months; actual restricted mean: 22.6 vs 20.1 months, respectively) (table 1). These results demonstrate clinically important improvements in Q-TWiST for the dostarlimab+CP versus CP group in both MMRp/MSS and dMMR/MSI-H populations; mean survival gains were 2.6 and 5.4 months, respectively. Similar outcomes were observed with Grade ≥2 AEs included in toxicity definition.

Conclusion In patients with AR EC, dostarlimab+CP had significantly longer quality-adjusted survival time than CP alone, indicating that dostarlimab+CP improves survival while preserving Q-TWiST.

Funding GSK213361. Editorial support provided by Fishawack Health, funded by GSK.

View this table:
Abstract #267 Table 1

Duration of Q-TWIST

Disclosures DC has received consultation and speaking fees for Astra Zeneca, Eisai, GSK, Immunogen, and Seagen/Genmab.

LB has received grants/research support from AstraZeneca, honoraria/consulting fees from Onsanger, and participation in a company sponsored speakers’ bureau for MSD.

RLC has received grants/research support from AstraZeneca, Clovis, Genelux, Genmab, Merck, Immunogen, and Roche/Genentech, consulting fees from Agenus, Alkermes, AstraZeneca, Clovis, Deciphera, Genelux, Genmab, GSK, Immunogen, OncoQuest, Onxerna, Regeneron, Roche/Genentech, Novocure, Merck, and Abbvie, honoraria from AstraZeneca, Clovis, Roche/Genentech, and Merck and participation on a Data Safety Monitoring Board or Advisory Board for VBL Therapeutics and Eisai/BMS.

OZ, SG, MGT, AR, RA and CMc have no conflicts of interest to disclose.

EM has received honoraria/consultation fees from Onc Live/Chemotherapy Foundation Symposium.

CMa has received institutional research funding from The National Cancer Institute, Syros, Deciphera, Astellas Pharma, Seagen, Genmab, EMD Serono, Merck, Regeneron, Moderna, AstraZeneca, GSK, AvengeBio and Genentech.

LCH has received honoraria/consultation fees from Amgen, AstraZeneca, Clovis Oncology, Eisai, GSK, Janssen, MSD, Novartis, Pfizer, PharmaMar, and Roche..

MP has received grants/research support from GSK and honoraria/consultation fees from GSK, Merck, Eisai, Clovis Oncology, Immunogen, and AstraZeneca.

LG has received institutional grants from Pfizer, Merck Sharp & Dohme, Karyopharm, Tesaro, Alkermes, GSK, Immunogen Inc and Roche and honoraria/consultation fees from GSK, Merck, Eisai, Eisai-Merck, Alkermes, and Novocure.

NC has participated in advisory boards for GSK, Toray, Takeda, Umoja, Kartos, Novita, and Zentalis.

BJM has received honoraria for speaking/consultation from Acrivon, Adaptimmune, Agenus, Akeso Bio, Amgen, Aravive, AstraZeneca, Bayer, Clovis, Easai, Elevar, EMD Merck, Genmab/Seagen, GOG Foundation, Gradalis, Heng Rui, Immunogen, Karyopharm, Iovance, Laekna Health Care, Merck, Mersana, Myriad, Novartis, Novocure, OncoC4, Panavance, Pieris, Pfizer, Puma, Regeneron, Roche/Genentech, Sorrento, Tesaro/GSK, US Oncology Research, VBL, Verastem, and Zentalis

BP has received grants/research support from Tesaro/GSK, Merck, AstraZeneca, Karyopharm, Sutro, Immunogen, VBL Therapeutics, Onconova,clovis, Genentech, Mersana, Ceslion, Takada, Incyte, Toray, and Seagen and honoraria/consultation fees from Tesaro/GSK, Merck, AstraZeneca, Eli Lilu, Sutro, SeaGen, Eisai, Natera, and GOG Partners.

JG and OA are employees of GSK.

MRM has received institutional research grants from Allarity, Apexigen, AstraZeneca, Boehringer Ingelheim, Clovis, GSK, Novartis, and Ultimovacs, been a trial chair for Deciphera, Mersana, and NuvationBio, been an invited speaker for AstraZeneca, GenMab, GSK, Mersana, Seagen, and Takeda, been a member of board of directors and holds stocks and shares for Karyopharm and Sera Prognostics.

https://doi.org/10.1136/ijgc-2023-ESGO.13

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.